REFERENCES

3. NIH3 Guidance on the use of high-titer convalescent plasma against SARS-CoV-2.
4. IDSA guidance on nirmatrelvir/ritonavir (Paxlovid) for the treatment of COVID-19 in adults (≥12 years old).
6. Remdesivir (VekluryTM) Package Insert (Prescribing Information) with the extended approval for outpatient use: veklury_pi.pdf (gilead.com).
7. Paxlovid EUA Fact Sheet for Healthcare Providers: Paxlovid™ Dosing:10
8. Molnupiravir18,19
11. EMA approval of bebtelovimab for treatment of COVID-19 in adults 18 years of age and older who have COVID-19 infection and one or more COVID-19 risk factors, or are at high risk for progression to severe COVID-19.
12. CDC Health Alert Network Notice: High titer convalescent plasma in immunosuppressed patients: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm7110a1.htm
13. EMA Scientific Opinion of the Committee for Medicinal Products for Human Use (CHMP) on the marketing authorization of Convalescent Plasma (V plasma-2022-02-03.pdf). A reliable method of informing the public about this is an emergency use authorization (EUA) issued by the FDA. EUA for FDA has been authorized by the Food and Drug Administration (FDA) for the treatment of COVID-19.
14. Facilities must document that potential benefits and risks of molnupiravir treatment are discussed with the patient, and the patient is made aware of the fact that it is unapproved.
15. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19, but the fact that it is an unapproved drug should be communicated to the patient.
16. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
17. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
18. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
19. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
20. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
21. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
22. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
23. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
24. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
25. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
26. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
27. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
28. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
29. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
30. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
31. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
32. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
33. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
34. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
35. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
36. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
37. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
38. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
39. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
40. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
41. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
42. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
43. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
44. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
45. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
46. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
47. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
48. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.
49. Molnupiravir treatment can be given to pregnant women who are at high risk for progression to severe COVID-19.